Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver  by Murray, Michael et al.
FEBS 29678 FEBS Letters 579 (2005) 3669–3673Phospho-STAT5 accumulation in nuclear fractions from vitamin
A-deﬁcient rat liver
Michael Murraya,b,*, Alison M. Butlerb, Eva Fiala-Beera,b, Gloria M. Sua,b
a Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
b Department of Physiology and Pharmacology, University of New South Wales, NSW 2052, Australia
Received 13 May 2005; accepted 19 May 2005
Available online 8 June 2005
Edited by Robert BaroukiAbstract The growth hormone (GH)-responsive cytochrome
P450 (CYP) 2C11 is down-regulated in vitamin A-deﬁcient
(VAD) rat liver. This study assessed the impact of a VAD diet
on the hepatic Janus kinase-Signal Transducers and Activators
of Transcription (JAK-STAT) system that mediates GH signal-
ling. Nuclear tyrosine- and serine-phosphorylated STAT5 accu-
mulated in VAD liver, whereas nuclear JAK2 tyrosine kinase
and SHP-1 phosphatase were decreased. Tyrosine-phosphory-
lated SHP-1 was decreased to 36 ± 14% of control (P < 0.01),
indicating its impaired activation in VAD liver. Episodic GH
pulses increased nuclear phospho-STAT5, especially in control
liver, but nuclear phospho-JAK2 and phospho-SHP-1 were not
restored. CYP2C11 protein and testosterone 16a-hydroxylation
were decreased in VAD liver to 67 ± 16% and 76 ± 19% of con-
trol, and were further decreased by GH to 32 ± 8% and
30 ± 14% of control. Thus, hypo-responsiveness of JAK-STAT
in VAD liver is associated with impaired nuclear phospho-STAT
dephosphorylation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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P4501. Introduction
In rat liver, growth hormone (GH) regulates several cyto-
chromes P450 (CYPs) that mediate xenobiotic and endobiotic
biotransformation [1]; human CYP genes are also regulated by
GH [2]. GH activates the GH-receptor and recruits the Janus
kinase (JAK) which stimulates the phosphorylation of cyto-
plasmic signal transducers and activators of transcription
(STATs) [3–5]. Activated STATs translocate to the nucleus
and stimulate target gene transcription. Hepatic STAT5 may
act in concert with liver-speciﬁc transcription factors, includ-
ing HNF-4, to activate HNF6 expression [6] or antagonise
other transactivating factors, such as HNF3a [7].Abbreviations: CYP, cytochrome P450; EMSA, electrophoretic mobil-
ity shift assay; GH, growth hormone; JAK-STAT, Janus kinase-signal
transducers and activators of transcription; pS, phosphoserine; pY,
phosphotyrosine; SHP, SH2-containing phosphatase
*Corresponding author. Fax: +61 2 9351 4447.
E-mail address: michaelm@pharm.usyd.edu.au (M. Murray).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.05.052Diet modulates gene expression [8], but the mechanisms are
largely unclear. We have demonstrated that the GH-regulated
CYP2C11, CYP4A2 and IGF-I are down-regulated in vitamin
A-deﬁcient (VAD) male rat liver [9,10]. GH regulates hepatic
CYP2C11, and other genes, including CIS and cyclin D1
[11,12] via the JAK-STAT pathway [1]. A GH pulse stimulates
STAT5b phosphorylation on tyrosine699 and serine730 [13] and
binding of phospho-STAT to gene regulatory elements. Termi-
nation of gene transactivation involves the SH2-containing
phosphatases (SHPs) that dephosphorylate nuclear phospho-
STATs, enabling their return to the cytoplasm for activation
by further GH pulses [14,15]. Altered hepatic JAK-STAT sig-
nalling occurs in liver injury induced by endotoxin and alcohol
[16,17] and may also be secondary to extrahepatic injury [18].
The present study evaluated the hypothesis that dysregula-
tion of JAK-STAT signalling occurs in VAD rat liver. The
principal ﬁndings to emerge were that nuclear phospho-STAT5
accumulated in VAD rat liver and that this was associated with
dysregulation of nuclear phospho-JAK2 and phospho-SHP-1.
The GH-responsiveness of the JAK-STAT system in VAD
liver was diminished, a ﬁnding consistent with impaired phos-
pho-STAT5 dephosphorylation. Under these conditions the
expression and activity of the GH-regulated CYP2C11 were de-
creased in VAD liver and were further decreased by exogenous
GH administration.2. Materials and methods
2.1. Animals and preparation of hepatic fractions
Studies conformed to the guidelines of the Australian National
Health and Medical Research Council and Institutional Animal Ethics
Committees. Male Wistar rats (3 week old, ca. 60 g) were housed at
constant temperature and lighting (12 h light-dark cycle). Animals re-
ceived the VAD diet (ICN biochemicals, Seven Hills, NSW, Australia)
for 10 weeks; controls received the VAD diet containing retinyl acetate
(25 IU/g). In another experiment, groups of control and VAD rats
were administered saline or GH (125 lg/kg sc, 12 h for 7 days; N = 6
animals per group); this regimen reactivates hepatic CYP2C11 expres-
sion in hypophysectomised male rats [1]. Animals had free access to
water and diet.
Rats were killed under enﬂurane anaesthesia, and livers were re-
moved and perfused with cold saline. Hepatic nuclear, cytosolic and
microsomal fractions were isolated by diﬀerential ultracentrifugation.
2.2. Materials
[a-32P]-dCTP (3000 Ci/mmol), [14C]-testosterone (55 mCi/mmol),
Hyperﬁlm-MP, ACS II, Hybond-N+ ﬁlters and reagents for enhanced
chemiluminescence were from Amersham Australia (North Ryde,
NSW). Biochemicals were from Sigma (St. Louis, MO) or Boehrin-
ger-Mannheim (Castle Hill, Australia). Recombinant GH was a giftblished by Elsevier B.V. All rights reserved.
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resis were from Bio-Rad (Richmond, CA) and analytical grade re-
agents were from Ajax Chemicals (Sydney, Australia).
Antibodies against STAT3 (sc-482), STAT5 (sc-835) and phosphoser-
ine-STAT5 (pS-STAT5; sc-12893), anti-RXRa (sc-553) were from San-
ta Cruz Biotechnology (Santa Cruz, CA). Antibodies against JAK2 (cat
06-255) and phosphotyrosine (pY-4G10; cat 05-321) were from Auspep
(Parkville, VIC, Australia). The anti-SHP-1 (anti-PTP-1C clone 52; cat
70317320) was from Sapphire Bioscience (Crows Nest, NSW, Austra-
lia). The CYP2C11 antibody was described previously [19].
2.3. Isolation of nuclear and cytosolic fractions
Nuclear and cytosolic protein extracts were prepared from freshly
isolated rat liver essentially as described [20]. Brieﬂy, liver pieces were
homogenised in NP buﬀer (2 mM dithiothreitol, 2 lg/ml aprotinin,
1 lg/ml pepstatin, 1 lg/ml leupeptin, 0.4 mM sodium orthovanadate,
1 mM sodium ﬂuoride and 0.5 mM phenylmethylsulfonyl ﬂuoride)
containing 300 mM sucrose, 0.15 mM spermine, 0.5 mM spermidine,
and 10 mM HEPES (pH 8.0) and centrifuged at 800 · g for 5 min.
The nuclear pellet was layered over 10 mM HEPES buﬀer (pH 8.0)
containing 0.88 M sucrose, precipitated with 0.3 M KCl, resuspended
in 10 mM HEPES buﬀer (pH 8.0) that contained 0.88 M sucrose and
0.3 M KCl and centrifuged at 100 000 · g for 15 min. The resultant
suspension was dialysed for 3 h against NP buﬀer containing 0.1 M
KCl, 20% glycerol, 0.2 mM EDTA and 20 mM HEPES (pH 8.0),
and stored in liquid nitrogen.
The post-800 g supernatant (above) was diluted with 2 volumes of
NP buﬀer, containing 0.1 M KCl, 20% glycerol, 0.2 mM EDTA and
20 mM HEPES (pH 8.0). Cytosolic and microsomal fractions were ob-
tained after centrifugation at 100 000 · g for 1.5 h and were stored in
liquid nitrogen.
2.4. Immunoprecipitation and Western blotting of rat liver subcellular
fractions
Hepatic nuclear (50 lg protein [21]) or cytosolic extracts (100 lg)
were incubated overnight at 4 C with 4G10 anti-pY (1 lg) antibodies
in 100 ll of immunoprecipitation buﬀer (1% Triton X-100, 0.5% Non-
idet NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM so-
dium vanadate, 0.2 mM phenylmethylsulfonylﬂuoride, 1 lg/ml
aprotinin, 1 lg/ml leupeptin, 1 lg/ml pepstatin and 10 mM HEPES,
pH 7.4). Immune precipitates were bound to 50% Protein A-Sephar-
ose-CL4B (Sigma) for 2 h, centrifuged at 14 000 · g and washed three
times with immunoprecipitation buﬀer. Samples were boiled for 10 min
in 30 ml of buﬀer (3% sodium dodecylsulfate, 10% b-mercaptoethanol,
20% glycerol, 0.002% bromophenol blue and 400 mM Tris–HCl, pH
6.8) and electrophoresed in 7.5% sodium dodecylsulfate-polyacryl-
amide gels. After transfer to nitrocellulose (Protran; Schleicher and
Schuell, Dassel, Germany) ﬁlters were probed with antibodies
(0.5 lg/ml). Immunoblot analysis of proteins in diﬀerent liver fractionsFig. 1. STAT5 and STAT3 immunoreactive proteins in nuclear and cytosolic
weeks. Immunoblots representative of two animals are shown (of N = 6 animwas performed on the same ﬁlter; ﬁlm exposure times were constant.
After blotting, ﬁlters were stained with amido black (Sigma) to conﬁrm
protein loading.
Immunoblotting for microsomal CYP2C11 protein and measure-
ment of microsomal testosterone hydroxylation was performed as de-
scribed previously [19].
2.5. Electrophoretic mobility shift assays
The double-stranded electrophoretic mobility shift assay (EMSA)
probe was the STAT5b element from the b-casein gene 5 0-ﬂank: 5 0-
GGA-CTT-CTT-GGA-ATT-AAG-GGA-3 0 and 5 0-GTC-CCT-TAA-
TTC-CAA-GAA-GTC-C-3 0 [4]. Reactions containing 100 fmoles of
end-labelled probe and 10 lg nuclear protein were incubated for
20 min at room temperature and 10 min at 4 C in 10 mM Tris–HCl
buﬀer (pH 7.5), containing 50 mM NaCl, 1 mM MgCl2, 0.5 mM
EDTA, 0.5 mM dithiothreitol, 4% glycerol and 1 lg poly(2 0-deoxyi-
nosinic-2 0-deoxycytidylic acid) and then resolved on 5% polyacryl-
amide gels in 90 mM Tris–HCl (pH 7.5), containing 90 mM boric
acid, and 2.5 mM EDTA [22]. In supershift experiments, protein was
incubated with rabbit polyclonal c-Jun or c-Fos antibodies (2 lg) for
1 h at 4 C prior to the binding reaction; an anti-ubiquitin antibody
(Santa Cruz) was used as a negative control. Cold competition exper-
iments included 200-fold excess of the unlabelled STAT5b probe. Fol-
lowing electrophoresis, gels were dried and autoradiographed.
2.6. Statistics
Data are presented as means ± S.D. Diﬀerences between means were
detected using one-way analysis of variance and Fishers PLSD test.3. Results
3.1. Eﬀect of a VAD diet on STAT expression in rat liver
In nuclear fractions, two STAT5-immunoreactive protein
signals were detected near 85 and 90 kD (Fig. 1) and a minor
band at lower molecular weight. Compared with control, the
signal near 85 kD accumulated in VAD fractions and the
upper band was less intense. In cytosolic fractions two signals
were also observed in the 85–90 kD region, with the higher
molecular weight species more prominent in control liver. In
comparison, STAT3 immunoblots in nuclear and cytosolic
fractions exhibited a single band (85 kD; Fig. 1). Intake of
the VAD diet increased nuclear STAT3 expression to
198 ± 12% of control (P < 0.001). To validate the subcellular
fractionation we immunoblotted for oct-1, which was presentfractions from male rats that received the control or VAD diet over 10
als/group).
Fig. 3. Binding of a 32P-labelled double stranded oligonucleotide
containing the b-casein gene promoter STAT5b element (100 fmol) to
(A) hepatic nuclear proteins (10 lg) from rats that received control or
VAD diets ± GH for 10 weeks, and (B) Supershift and cold compe-
tition experiments in nuclear fractions from control + GH rats.
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changed in VAD liver (not shown).
3.2. Episodic GH administration and nuclear STAT5 regulation
To test the responsiveness of the JAK-STAT system in VAD
and control rat liver, we administered GH by an episodic reg-
imen that restored gene expression in hypophysectomised male
rat liver [1]. In control rats GH increased nuclear STAT5 pro-
tein, especially the signal at lower molecular weight (Fig. 2). A
similar, but less pronounced, increase in nuclear STAT5 pro-
tein occurred after GH administration to VAD rats. Thus,
GH increased total nuclear STAT5 protein to 2.8-fold of
control (P < 0.001) and to 2.4-fold of untreated levels in
VAD animals (P < 0.001).
Tyrosine phosphorylated-(pY)-STAT5, comigrated with the
lower molecular weight signal on immunoblots. pY-STAT
expression was low in immune precipitates from control nucle-
ar fractions, but was detected in VAD liver (Fig. 2).
pY-STAT5 was less responsive to GH in VAD liver; similar
ﬁndings were noted with phosphoserine-(pS)-STAT5 (Fig. 2).
By comparison, RXRa expression was similar in all nuclear
fractions and amido black staining of the 85–120 kD protein
region on nitrocellulose ﬁlters conﬁrmed similar loading. Thus,
STAT5 phosphorylation was dysregulated in VAD liver and
was less responsive to GH. EMSA ﬁndings were consonant
with immunoblot data. phospho-STAT5 was present in a
DNA-binding form in VAD nuclear fractions, but was unde-
tectable in control liver; GH increased the EMSA signal in
VAD and especially control liver (Fig. 3(A)). Supershift exper-
iments conﬁrmed the presence of pY- and pS-STAT5 in the re-
tarded band (Fig. 3(B)).
3.3. Eﬀect of the VAD diet on JAK2 and SHP-1 expression in
rat liver
Because pY-STAT5 was more abundant in VAD liver we
measured the expression of JAK2, which phosphorylates
STAT5 on tyrosine699, and SHP-1, which terminates STAT5
signalling [15]. Cytosolic JAK2 and SHP-1 expression wasFig. 2. Representative immunoblots of nuclear STAT5, pY-STAT5,
pS-STAT5 and RXRa in control and VAD rat liver; signals after
episodic GH (125 lg/kg sc 12 h for 7 days) are indicated. Amido Black
staining of proteins on nitrocellulose ﬁlters (85–120 kD region) is
shown.unchanged from control (not shown), but their nuclear expres-
sion was decreased in VAD liver (Fig. 4). In fractions from
VAD liver pY-JAK2 was absent and pY-SHP-1 was decreased
to 36 ± 14% of control (P < 0.001; Fig. 4). Episodic GH in-
creased nuclear pY-SHP-1 to 146 ± 28% of control;
P < 0.001, but did not normalise expression in VAD liver
(62 ± 16% of control; P < 0.01; Fig. 4). CYP2C11 activity
and protein were decreased to 76 ± 19% and 67 ± 16% of con-
trol in VAD liver; GH administration further decreased these
to 30 ± 14% control and 32 ± 8% of control, respectively.4. Discussion
The pulsatility of GH secretion in the male rat regulates he-
patic gene expression via the JAK2-STAT5 pathway [1]. We
have reported previously that the GH-regulated CYP2C11,
CYP4A2 and IGF-I are down-regulated in VAD liver
[9,10,19,23]. The present study evaluated whether the JAK-
STAT pathway might also be dysregulated in these livers.
The major ﬁndings to emerge were that nuclear phospho-
STAT5 accumulated in VAD liver and that the JAK-STAT
system was less responsive to episodic GH. In VAD liver,
the expression and function of the GH-regulated CYP2C11
was decreased and was further decreased after administration
of pulsatile GH.
Cytosolic JAK2 is recruited to the GH-receptor following
GH-activation and mediates the phosphorylation of cytoplas-
mic STAT5, enabling their nuclear translocation [3,5]. Cytoso-
plasmic STAT expression was largely unaﬀected by dietary
vitamin A-status. In contrast, nuclear phospho-STAT5 accu-
mulated in VAD liver and was associated with decreased
expression of the nuclear JAK2 tyrosine kinase and SHP-1
phosphatase. It has been proposed that nuclear JAK2 phos-
phorylates SHP-1, which then terminates nuclear STAT5b sig-
nalling and enables the recycling of dephosphorylated STAT5b
Fig. 4. (A) Representative JAK2 and SHP-1 immunoblots in hepatic nuclear protein fractions. Nuclear pY-JAK2 and pY-SHP-1 expression in pY-
immune precipitates from control and VAD rats are shown. (B) After densitometry pY-SHP-1 expression was diﬀerent from control: \P < 0.01,
\\P < 0.001; and VAD: P < 0.05 (N = 6 animals/group).
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SHP-1 in VAD liver impairs STAT5 dephosphorylation, lead-
ing to the nuclear retention of phospho-STAT5 and the dimin-
ished responsiveness of the system to further GH pulses.
Some STAT proteins are constitutively phosphorylated on
serine and undergo tyrosine phosphorylation after ligand acti-
vation [13]. Tyrosine and serine/threonine phosphorylation ap-
pears to be required for regulation of STAT5-dependent gene
activation by interferon, prolactin, interleukin-2 and GH
[11,24–27]. In the present study, nuclear pS-STAT5 accumu-
lated in VAD liver and could contribute to JAK-STAT den-
sensitisation to GH.
Much of the information on GH-regulation of hepatic genes
by the JAK-STAT system comes from studies in hypophysec-
tomised rats and in cells, in which there is a GH-free back-
ground [4,13,28,29]. The present study is one of relatively
few that have been undertaken in animals with intact hypotha-
lamic–pituitary–gonadal axes characterised by physiological
GH pulses. Several reports of JAK-STAT dysregulation in al-
tered physiological and pathological conditions have ap-
peared. In common with VAD liver, JAK2 and STAT5
phosphorylation was impaired in fasted rats and STAT5 was
desensitised to incoming GH pulses [30]. Diminished GH
responsiveness of JAK2-STAT5b also occurred in chronic re-
nal failure [31] and in sepsis [32]. Like the VAD diet, cytokine
release by lipopolysaccharide elicited hepatic GH resistance at
the level of STAT5 phosphorylation [32]. Similarly, endotoxin
decreased STAT5b phosphorylation in response to GH, with-
out altering total STAT5b expression [16]. Post-GH-receptor
signalling defects are common to these models and may con-
tribute to impaired CYP2C11 regulation in liver of VAD
and cytokine-treated rats [33].
Other treatments may exert diﬀerent eﬀects on the
JAK-STAT pathway. Ethanol decreased STAT5b and phos-
pho-STAT5b expression, and increased cytosolic JAK2 and
p-JAK2, but GH-receptor expression was unchanged [24].
Thus, impaired STAT5b phosphorylation by cytosolic JAK2was evident, in contrast with the eﬀect of the VAD diet on nu-
clear JAK2 and SHP-1.
In summary, impaired JAK-STAT signalling in VAD rat liver
adds to the evidence that this pathway may be altered in certain
pathophysiological states. Dysregulated nuclear phospho-
STAT expression is closely associated with impaired expression
of SHP-1 that dephosphorylates pY-STAT5. Desensitisation of
the JAK-STAT system in VAD liver may contribute to down-
regulation of GH-responsive genes, such as CYP2C11.
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